Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Psyence Biomedical ( (PBM) ) just unveiled an update.
On April 17, 2026, Psyence BioMed welcomed reports that the U.S. administration is preparing an executive order to further evaluate ibogaine’s safety and therapeutic potential for PTSD, addiction and other serious mental health conditions. The company said such action underscores the need for rigorous, regulated research to move patients away from unregulated access and toward controlled clinical pathways.
Management highlighted Psyence BioMed’s global leadership in GMP-compliant ibogaine manufacturing through PsyLabs and its development of an ethically sourced supply chain rooted in ibogaine’s native African ecosystem. As global interest and possible regulatory evolution around ibogaine accelerate, the company argued its integrated platform positions it to support large-scale research and future therapeutic development.
PsyLabs already exports psychedelic active pharmaceutical ingredients, including psilocybin products, to regulated markets in Canada, the U.K., Portugal and Slovenia from an ISO 22000 and GMP-compliant facility. Psyence BioMed framed the potential U.S. policy shift as a catalyst that could increase demand for standardized, traceable ibogaine, reinforcing its strategic position but cautioned there is no assurance any executive order will be issued or will directly benefit its programs.
More about Psyence Biomedical
Psyence Biomedical Ltd., trading on Nasdaq as PBM, is a clinical-stage biopharmaceutical company developing nature-derived psilocybin and ibogaine therapies for mental health disorders. It operates a vertically integrated model spanning ethical sourcing, GMP-compliant manufacturing via its PsyLabs investment, and clinical development aimed at FDA-approved psychedelic-based treatments.
Average Trading Volume: 207,494
Technical Sentiment Signal: Sell
Current Market Cap: $2.94M
See more insights into PBM stock on TipRanks’ Stock Analysis page.